ETH spin-off Memo Therapeutics is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer.

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center